Literature DB >> 34298749

Genetic Landscape of Male Breast Cancer.

Fernando Augusto Batista Campos1, Etienne Rouleau2, Giovana Tardin Torrezan3,4, Dirce Maria Carraro3,4, José Claudio Casali da Rocha5, Higor Kassouf Mantovani6, Leonardo Roberto da Silva6, Cynthia Aparecida Bueno de Toledo Osório7, Solange Moraes Sanches1, Sandrine M Caputo8,9, Elizabeth Santana Dos Santos1,10.   

Abstract

Male breast cancer (MBC) is now considered molecularly different from female breast cancer (FBC). Evidence from studies indicates that common genetic and epigenetic features of FBC are not shared with those diagnosed in men. Genetic predisposition is likely to play a significant role in the tumorigenesis of this rare disease. Inherited germline variants in BRCA1 and BRCA2 account for around 2% and 10% of MBC cases, respectively, and the lifetime risk of breast cancer for men harboring BRCA1 and BRCA2 mutations is 1.2% and 6.8%. As for FBC, pathogenic mutations in other breast cancer genes have also been recently associated with an increased risk of MBC, such as PALB2 and CHEK2 mutations. However, while multigene germline panels have been extensively performed for BC female patients, the rarity of MBC has resulted in limited data to allow the understanding of the magnitude of risk and the contribution of recently identified moderate penetrance genes of FBC for MBC predisposition. This review gathers available data about the germline genetic landscape of men affected by breast cancer, estimated risk associated with these genetic variants, and current guidelines for clinical management.

Entities:  

Keywords:  BRCA1; BRCA2; genetic testing; hereditary breast cancer; male breast cancer

Year:  2021        PMID: 34298749     DOI: 10.3390/cancers13143535

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.

Authors:  Muriel Rolfes; Julika Borde; Kathrin Möllenhoff; Mohamad Kayali; Corinna Ernst; Andrea Gehrig; Christian Sutter; Juliane Ramser; Dieter Niederacher; Judit Horváth; Norbert Arnold; Alfons Meindl; Bernd Auber; Andreas Rump; Shan Wang-Gohrke; Julia Ritter; Julia Hentschel; Holger Thiele; Janine Altmüller; Peter Nürnberg; Kerstin Rhiem; Christoph Engel; Barbara Wappenschmidt; Rita K Schmutzler; Eric Hahnen; Jan Hauke
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

2.  Development of male breast cancer in a patient with prostate cancer during androgen deprivation therapy.

Authors:  Hiroya Mizusawa; Akira Komatsu; Yuji Mimura; Toshitaka Maejima
Journal:  IJU Case Rep       Date:  2022-01-11

Review 3.  An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations.

Authors:  Fabiana Baroni Alves Makdissi; Silvana S Santos; Almir Bitencourt; Fernando Augusto Batista Campos
Journal:  Int Braz J Urol       Date:  2022 Sep-Oct       Impact factor: 3.050

4.  Highlights of the 'I Congress ecancer Choosing Wisely' March 30 and 31, 2022 Santa Cruz, Bolivia.

Authors:  Ronald Limón; Lucia Reynolds; Erick Rocha; Lucia Richter; Mario Gianella; Oscar Niño de Guzman; Gerson Mejia; José Nina; Wendy Rojas; Lijia Avilés; Iván Maldonado; Cristian Pacheco; Claudio Martín; Maria G Cervantes; Federico Bakal; Eduardo Cazap
Journal:  Ecancermedicalscience       Date:  2022-08-04

Review 5.  The Viral Origin of Human Breast Cancer: From the Mouse Mammary Tumor Virus (MMTV) to the Human Betaretrovirus (HBRV).

Authors:  Generoso Bevilacqua
Journal:  Viruses       Date:  2022-08-01       Impact factor: 5.818

6.  Identification and Characterization of an Exonic Duplication in PALB2 in a Man with Synchronous Breast and Prostate Cancer.

Authors:  Ahmed Bouras; Cyril Lafaye; Melanie Leone; Zine-Eddine Kherraf; Tanguy Martin-Denavit; Sandra Fert-Ferrer; Alain Calender; Nadia Boutry-Kryza
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.